REG - GSK PLC GlaxoSK Capital PLC GlaxoSK Kabush.K GSK Capital B.V. - Publication of EMTN Suppl.Prospcts

GSKAnnouncement

20/12/2023 16:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231220:nRST5181Xa&default-theme=true

RNS Number : 5181X  GSK PLC  20 December 2023

Issued: 20 December, 2023, London UK

 

GSK plc Publication of Supplement to Prospectus

 

 

 

GSK plc today announced that the following supplement dated 20(th) December,
2023 to the prospectus dated 8(th) August, 2023 has been approved by the
Financial Conduct Authority and is available for viewing:

 

GSK plc, GlaxoSmithKline Capital plc, GSK Capital B.V. and GSK Capital K.K.
£20,000,000,000 Euro Medium Term Note Programme

 

Copies of the supplement to the prospectus and the document incorporated by
reference within it have been submitted to the Financial Conduct Authority's
National Storage Mechanism (NSM) submission portal via the Electronic
Submission System (ESS) and will shortly be available for inspection at and
can be downloaded from:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

For further information, please contact:

Company Secretary

GSK plc

980 Great West Road

Brentford

Middlesex

TW8 9GS

United Kingdom

company.secretary@gsk.com (mailto:company.secretary@gsk.com)

Enquiries:

 UK Media enquiries:                   Tim Foley       +44 (0) 20 8047 5502  (London)
 European Analyst/Investor enquiries:  Nick Stone      +44 7717 618 834      (London)

                                       James Dodwell   +44 7881 269 066      (London)

 

BASIS ON WHICH YOU MAY ACCESS THE SUPPLEMENT TO THE PROSPECTUS

 

Please note that the information contained in the supplement to the prospectus
may be addressed to and/or targeted at persons who are residents of particular
countries (specified in the prospectus) only and is not intended for use and
should not be relied upon by any person outside these countries and/or to whom
the offer contained in the supplement to the prospectus is not addressed.
Prior to relying on the information contained in the supplement to the
prospectus you must ascertain from the supplement to the prospectus whether or
not you are part of the intended addressees of the information contained
therein.

 

Your right to access this service is conditional upon complying with the above

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at
https://www.gsk.com/en-gb/company/ (https://www.gsk.com/en-gb/company/) .

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PSPNKKBNABDDDBB